Quick Facts
  • house icon next to a calendar outline
    Year Built:
    1970
  • icon of stretcher
    Number of Beds:
    38 beds
  • icon of person with first aid kit
    Number of Physicians:
    1

Multidisciplinary Mesothelioma Care at Georgetown Lombardi Comprehensive Cancer Center

Doctors at the Georgetown Lombardi Comprehensive Cancer Center take a patient-first philosophy to cancer care, a personalized treatment approach that has helped the institute earn a reputation as the top cancer center in the D.C. area. Georgetown Lombardi Comprehensive Cancer Center is a regional leader in the diagnosis and treatment of cancer and a model for comprehensive, multidisciplinary cancer centers across the nation.

The facility is also Washington, D.C.’s only National Cancer Institute-designated comprehensive cancer center. NCI comprehensive cancer centers are considered to be the most advanced and qualified cancer centers nationwide. People diagnosed with mesothelioma often receive the best treatment at NCI-designated cancer centers since these facilities are typically more equipped to treat rare cancers.

Patients with asbestos-related cancers can seek a wide range of cutting-edge therapies at the Georgetown Lombardi Comprehensive Cancer Center. For example, asbestos lung cancer patients can visit the institute’s Lung Cancer Center, where they can attend weekly meetings with a cancer care team handpicked to meet their individual needs.

In addition to its specialty departments in medical, surgical and radiation oncology, the Georgetown Lombardi Comprehensive Cancer Center offers 11 site-specific cancer centers and a comprehensive pain center.  The Georgetown Lombardi Comprehensive Cancer Center was one of the first cancer programs in the nation to be American Society of Clinical Oncology’s acclaimed Quality Oncology Practice Initiative Certification Program-recognized. Each year the cancer center diagnoses more than 1,400 new cases of cancer and serves more than 70,000 outpatients.

Georgetown Lombardi Comprehensive Cancer Center’s Peritoneal Surface Malignancies Program

The Georgetown Lombardi Comprehensive Cancer Center takes a multidisciplinary, patient-centered approach to mesothelioma treatment. Patients with pleural, peritoneal or other forms of mesothelioma can consult with a team of expert doctors to plan an effective course of treatment. Therapy typically involves some combination of surgery, chemotherapy, radiation therapy and supportive care.

In 1993, the cancer center launched the Peritoneal Surface Malignancies program to better serve patients with mesothelioma and other difficult cancers of the abdomen and pelvis. The Georgetown Lombardi Comprehensive Cancer Center and three other cancer centers worldwide have treated a combined 300 peritoneal mesothelioma patients using a procedure Dr. Paul Sugarbaker pioneered. The procedure combines cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, known as HIPEC. 

Doctors at the Georgetown Lombardi Comprehensive Cancer Center have created a systematic guide to help determine the best candidates for treatment at the Peritoneal Surface Malignancies program. The first step is presurgical screening, during which a team of doctors review the patient’s imaging scans and other test results before a face-to-face meeting.

Next, the patient meets with a surgical oncologist at the cancer center’s Oncology Specialty Center. In the initial evaluation that follows, a team of doctors explains the cancer diagnosis and imaging scan results before describing possible approaches to treatment. The meeting also includes a physical examination.

Before cancer surgery, patients must undergo a surgical evaluation called a diagnostic workup. This step includes patient education, further testing (which may include an EKG heart test, blood tests and imaging scans) and a consultation with an enterostomal therapist. After surgery, patients can expect to spend about 21 days at the hospital recovering.

Pleural Mesothelioma and Lung Cancer Treatment Georgetown Lombardi Comprehensive Cancer Center

Patients diagnosed with lung cancer can seek treatment at the Georgetown Lombardi Comprehensive Cancer Center’s Lung Cancer Center. In a single appointment, patients meet all members of their cancer care team in one room. Depending on the patient’s unique needs, the team of specialists may include surgeons, medical oncologists, radiation oncologists, radiologists, lung pathologists, nutritionists or several other support staff members.

Because the three primary types of treatment for lung cancer are surgery, chemotherapy and radiation therapy, coordination among the doctors administering these therapies is crucial. At the Lung Cancer Center, patients can establish relationships with all of their care providers in one setting. Doctors will inform patients about all aspects of the treatment plan and answer any questions in a single weekly meeting. Patients are encouraged to bring a friend or loved one to the Lung Cancer Center for support.

Georgetown Lombardi Comprehensive Cancer Center’s High-Level Cancer Research

The Georgetown Lombardi Comprehensive Cancer Center has a strong commitment to research. The cancer center not only advances the quality of cancer treatment and supportive care as a whole, but also brings cutting-edge treatments to its patients.

The success of current treatments depends on the results of past clinical trials. Doctors at the Georgetown Lombardi Comprehensive Cancer Center encourage patients to participate in these human studies, which aim to evaluate the safety and effectiveness of new drugs, drug combinations or treatment approaches.

Although there is no guarantee that new treatments from clinical trials will be better than current therapies, patients may gain access to innovative therapies that are not available elsewhere.

Mesothelioma Clinical Trials at Georgetown Lombardi Comprehensive Cancer Center

  • A phase I clinical trial studying the use of atezolizumab, a novel immunotherapy drug, in combination with chemotherapy, surgery and possibly radiation therapy for pleural mesothelioma. The study drug may be used either before or after surgery.
  • A phase I dose escalation study measuring the tolerability of MCY-M11 when administered as an intraperitoneal infusion for peritoneal mesothelioma after recurrence of disease following chemotherapy.
  • A phase II clinical trial studying the use of Opdivo (nivolumab) and Yervoy (ipilimumab), an immunotherapy combination, for patients with rare tumors such as mesothelioma.